6zz1
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Crystal structure of MLKL executioner domain in complex with a covalent inhibitor== | ==Crystal structure of MLKL executioner domain in complex with a covalent inhibitor== | ||
| - | <StructureSection load='6zz1' size='340' side='right'caption='[[6zz1]]' scene=''> | + | <StructureSection load='6zz1' size='340' side='right'caption='[[6zz1]], [[Resolution|resolution]] 1.64Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6ZZ1 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6ZZ1 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6zz1]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6ZZ1 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6ZZ1 FirstGlance]. <br> |
| - | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6zz1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6zz1 OCA], [http://pdbe.org/6zz1 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6zz1 RCSB], [http://www.ebi.ac.uk/pdbsum/6zz1 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6zz1 ProSAT]</span></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=QOK:7-(2-methoxyethoxymethyl)-1,3-dimethyl-purine-2,6-dione'>QOK</scene></td></tr> |
| + | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[6zvo|6zvo]], [[6zle|6zle]], [[6zpr|6zpr]]</div></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6zz1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6zz1 OCA], [http://pdbe.org/6zz1 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6zz1 RCSB], [http://www.ebi.ac.uk/pdbsum/6zz1 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6zz1 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/MLKL_HUMAN MLKL_HUMAN]] Required for the execution of programmed necrosis.<ref>PMID:22265414</ref> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | As an alternative pathway of controlled cell death, necroptosis can be triggered by tumor necrosis factor via the kinases RIPK1/RIPK3 and the effector protein mixed-lineage kinase domain-like protein (MLKL). Upon activation, MLKL oligomerizes and integrates into the plasma membrane via its executioner domain. Here, we present the X-ray and NMR costructures of the human MLKL executioner domain covalently bound via Cys86 to a xanthine class inhibitor. The structures reveal that the compound stabilizes the interaction between the auto-inhibitory brace helix alpha6 and the four-helix bundle by stacking to Phe148. An NMR-based functional assay observing the conformation of this helix showed that the F148A mutant is unresponsive to the compound, providing further evidence for the importance of this interaction. Real-time and diffusion NMR studies demonstrate that xanthine derivatives inhibit MLKL oligomerization. Finally, we show that the other well-known MLKL inhibitor Necrosulfonamide, which also covalently modifies Cys86, must employ a different mode of action. | ||
| + | |||
| + | Locking mixed-lineage kinase domain-like protein in its auto-inhibited state prevents necroptosis.,Rubbelke M, Fiegen D, Bauer M, Binder F, Hamilton J, King J, Thamm S, Nar H, Zeeb M Proc Natl Acad Sci U S A. 2020 Dec 14. pii: 2017406117. doi:, 10.1073/pnas.2017406117. PMID:33318170<ref>PMID:33318170</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 6zz1" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| - | [[Category: Bauer M]] | + | [[Category: Bauer, M]] |
| - | [[Category: Fiegen D]] | + | [[Category: Fiegen, D]] |
| - | [[Category: Nar H]] | + | [[Category: Nar, H]] |
| + | [[Category: Lipid binding protein]] | ||
| + | [[Category: Necroptosis]] | ||
Revision as of 09:05, 6 January 2021
Crystal structure of MLKL executioner domain in complex with a covalent inhibitor
| |||||||||||
